10.6 C
New York
Sunday, April 14, 2024

Form as an incremental therapy

Tagrisso 80 mg (osimertinib) is an innovative and powerful incremental therapy specifically designed to target the mutated epidermal growth factor receptor (EGFR) in a very specific way. The drug works by blocking the EGFR-mediated cell signalling pathways in cells that have the EGFR mutation. This allows the drug to effectively target EGFR mutations in a very specific manner, allowing for improved or better responses from the treatment than other drugs used to treat EGFR-mediated diseases.

Stopping the altered signalling action

Tagrisso 80 mg is a tyrosine kinase inhibitor (TKI) and works by stopping mutated EGFR from producing its own receptors and consequently stopping the signals that proceed from them. This results in the inhibition of cell proliferation and ultimately death of the abnormal cells. This results in a better treatment response than other drugs used to treat those same types of cancer.

Approved for its use

The drug has been approved by the U.S. Food and Drug Administration (FDA) in 2019 to treat metastatic non-small cell lung cancer that has the EGFR T790M mutation. This mutation is considered to provide resistance to the first line of treatments which typically involves the use of anti-tumour monoclonal antibodies or chemotherapy. However, the use of Tagrisso 80 mg as an incremental therapy has proven to be highly effective in treating metastatic non-small cell lung cancer and has even been approved for use in the first-line setting.

Effective and standardised incremental therapy

Tagrisso 80 mg is considered to be an effective incremental therapy as its unique mode of action and specificity make it a valuable addition to the existing treatments for metastatic non-small cell lung cancer. The molecule is specifically targeted to patients with the EGFR T790M mutation, though it can also be used in non-T790M patients as an adjuvant therapy along with other drugs. This allows for greater flexibility in managing the disease and allows for better response rates when Tagrisso 80 mg is used as an incremental therapy.

Targeting mutation through the combined action

Additionally, Tagrisso 80 mg has been studied in combination with another drug called erlotinib, which also targets the mutation in a different way. This combination therapy has been found to be highly effective in treating a variety of cancers and is currently being used in clinical trials to see if it provides better outcomes than standard treatments.

Use in lung cancer patients

Tagrisso (osimertinib) is a medication used in the treatment of metastatic non-small cell lung cancer (NSCLC), specifically those patients whose tumours have a mutation in the epidermal growth factor receptor (EGFR). Administered as a tablet, Tagrisso is typically prescribed to patients with advanced, EGFR-mutated lung cancer who have certain primary or secondary mutations, or with tumours that have progressed despite prior EGFR inhibitor therapy.

Shrinkage of tumour

Tagrisso works by binding to the mutated EGFR, blocking signals to tumour cells and preventing them from growing and dividing. As a result, the tumour shrinks. In addition to inhibiting the growth of tumour cells, it also prevents them from becoming resistant to other therapy or medications.

Studies from clinical data

In clinical studies, a Tagrisso dose of 80 mg once daily has been shown to successfully treat superior overall tumour response rates and decreased the risk of disease progression versus placebo. In the ATALANTE trial, 65.7% of patients responded to Tagrisso 80 mg, compared to 6.9% taking the placebo. Furthermore, 65.8% of patients had a complete response to the Osimertinib 80 mg dose, versus 5.3% of patients taking the placebo, representing a statistically significant increase in overall response rate.

Results reproduce a survival time

Tagrisso has also been shown to significantly increase progression-free survival time, which measures how long a patient is able to live without the symptoms of the disease worsening. In the same ATALANTE trial, progression-free survival was 9.7 months for patients taking the Tagrisso 80 mg dose and 4.0 months for those taking the placebo.

Effects to be taken with precaution

Tagrisso is an effective and safe medication for treating metastatic NSCLC patients with EGFR-mutation tumours. In most cases, the benefits of using Tagrisso outweigh the potential side effects. Common side effects associated with the medication include fatigue, nausea, decreased appetite, diarrhoea, and constipation. In some cases, the medication may also cause skin reactions such as rash, itching, and dry skin. Tagrisso is usually taken in a facility monitored by a doctor or nurse, and patients should not stop taking the medication without consulting their doctor as doing so may reduce its effectiveness.


In conclusion, Tagrisso 80 mg is an innovative and powerful incremental therapy specifically designed to target the mutated epidermal growth factor receptor (EGFR). The drug is effective in stopping cell proliferation and death of abnormal cells and has been approved for the treatment of metastatic non-small cell lung cancer in the first-line setting. Additionally, it has been studied in combination therapy with other drugs, leading to even better response rates. This makes Tagrisso 80 mg an ideal incremental therapy for treating metastatic non-small cell lung cancer.

Also read about- Did you know about Rheumatoid arthritis

Related Articles

Stay Connected


Latest Articles